Literature DB >> 1517249

Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation.

T Dyrks1, E Dyrks, T Hartmann, C Masters, K Beyreuther.   

Abstract

Previously we have shown that the COOH-terminal 100 residues (A4CT) of the amyloid protein precursor (APP), which carry the sequence of the amyloid beta A4 protein of Alzheimer's disease at N-terminal position, form highly insoluble aggregates if expressed in the rabbit reticulocyte lysate and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Dyrks, T., Weidemann, A., Multhaup, G., Salbaum, J.M., Lemaire, H.-G., Kang, J., Müller-Hill, B., Masters, C. L., and Beyreuther, K. (1988) EMBO J. 7, 949-957). Here we report that aggregation of this COOH-terminal APP fragment A4CT and also of beta A4 itself depends on additional factors. In contrast to the reticulocyte expression system, expression of A4CT and beta A4 in the wheat germ expression system resulted in only monomeric forms. We have identified the factors which are capable of transforming both soluble A4CT and beta A4 into insoluble and aggregating molecules. Monomeric A4CT or beta A4 expressed in the wheat germ lysate could be transformed into aggregating molecules by the addition of metal-catalyzed oxidation systems. The addition of radical scavengers such as ascorbic acid, trolox, and amino acids prevented the aggregation process induced by the radical initiators. Thus, the aggregation of amyloidogenic APP fragments if analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis requires amino acid oxidation and protein cross-linking induced by radical generation systems.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517249

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Oxidative imbalance in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-Gon Lee; Gemma Casadesus; Jesus Avila; Kelly Drew; George Perry; Mark A Smith
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

2.  Neuroprotection in Alzheimer's disease - new strategies for treatment.

Authors:  A Nordberg
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  The mitochondrial permeability transition in neurologic disease.

Authors:  M D Norenberg; K V Rama Rao
Journal:  Neurochem Int       Date:  2007-03-04       Impact factor: 3.921

4.  Regional membrane phospholipid alterations in Alzheimer's disease.

Authors:  M R Prasad; M A Lovell; M Yatin; H Dhillon; W R Markesbery
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

5.  An anemia of Alzheimer's disease.

Authors:  N G Faux; A Rembach; J Wiley; K A Ellis; D Ames; C J Fowler; R N Martins; K K Pertile; R L Rumble; B Trounson; C L Masters; A I Bush
Journal:  Mol Psychiatry       Date:  2014-01-14       Impact factor: 15.992

Review 6.  Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal.

Authors:  Rajat Sandhir; Smriti Gupta
Journal:  World J Diabetes       Date:  2015-09-25

7.  Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction.

Authors:  T Tomiyama; H Kaneko; K i Kataoka; S Asano; N Endo
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

Review 8.  Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease.

Authors:  R J Mark; E M Blanc; M P Mattson
Journal:  Mol Neurobiol       Date:  1996-06       Impact factor: 5.590

Review 9.  Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Acta Neuropathol       Date:  2009-03-14       Impact factor: 17.088

10.  Alzheimer's disease: A hypothesis on pathogenesis.

Authors:  D Harman
Journal:  J Am Aging Assoc       Date:  2000-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.